Clinical Trial Update: Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for Relypsa evaluating ED acute hyperkalemia control and reduction (REDUCE) completed in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Failure

Drugs mentioned

• Relypsa

Snippet

Sponsor: Baylor College of Medicine | Conditions: Kidney Failure, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2019-05-09